Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

19931,035 citationsJournal Article

Authors

Michael J. Elliott · Kennedy Center

Ravinder N. Maini

Marc Feldmann

A. Long-Fox

P. Charles

Peter D. Katsikis · Charing Cross Hospital

Fionula M. Brennan · Charing Cross Hospital

Jean Walker

Hanny Bijl · Charing Cross Hospital

Abstract

Treatment with anti-TNF alpha was safe and well tolerated and resulted in significant clinical and laboratory improvements. These preliminary results support the hypothesis that TNF alpha is an important regulator in RA, and suggest that it may be a useful new therapeutic target in this disease.

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Monoclonal and Polyclonal Antibodies Research Autoimmune and Inflammatory Disorders Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Arthritis & Rheumatism

Volume 36, Issue 12, pp. 1681-1690

DOI: 10.1002/art.1780361206

Field-Weighted Citation Impact: 53.03